EDVA logo

ENDOVIA HEALTH SCIENCES INC

EDVANYSE AMERICAN
🏆 #5414 by market capEarnings Nov 17US Equity
$0.17▼ $0.01 (−3.54%)
Market closed · at close
🔔
Track EDVA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
88
Very Good
No chart data available for EDVA.

Trading Snapshot

Day Range
$0.17 – $0.18
52-Week Range
$0.16 – $13.40
Volume
$2.96B
Avg Volume
$2.43B
Shares Outstanding
6.4M
Next Earnings
Dec 12, 2026

Fundamentals Snapshot

Annual Revenue
$310,651
Last Q Revenue
$79,747
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—

Why Investors Own EDVA

  • ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 65% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EDVA logo

ENDOVIA HEALTH SCIENCES INC

EDVA
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$310,651▲ +34.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
65.1%▲ +3.6% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$96,612▲ +34.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$33,240▲ +34.9% YoY
StockOtter · stockotter.space

About ENDOVIA HEALTH SCIENCES INC

Endovia Health Sciences is a diversified cannabinoid-based health sciences platform. The company's strategy focuses on three main areas: commercializing differentiated cannabinoid-based pharmaceutical products internationally, advancing cannabinoid-based human and veterinary therapeutics through U.S. regulatory pathways, and developing consumer wellness and beverage products. This marks a strategic transformation from its prior operations as a beverage company.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2025

Latest News & Updates

🚀
CNBC·2h ago

ENDOVIA HEALTH SCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift EDVA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ENDOVIA HEALTH SCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.